TFPI inhibitors and methods of use

US9018167B2 · kind B2 · utility

Assignees

• Baxter International Inc. · US
• Baxter Healthcare SA · CH

Inventors

• Michael Dockal · Wien, AT
• Rudolf Hartmann · Bisamberg, AT
• Markus Fries · Wien, AT
• Friedrich Scheiflinger · Wien, AT
• Hartmut Ehrlich · Paris, FR
• Ulrich Reineke · Berlin, DE
• Frank Osterkamp · Berlin, DE
• Thomas Polakowski · Berlin, DE

Key dates

• Filing date: Mar 18, 2013
• Grant date: Apr 28, 2015
• Expiry date: Mar 18, 2033

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2500/20
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.